前列腺癌
恩扎鲁胺
奥拉帕尼
雄激素受体
多西紫杉醇
医学
PTEN公司
癌症研究
PARP抑制剂
离体
癌症
前列腺
体内
肿瘤科
比卡鲁胺
内科学
生物
细胞凋亡
PI3K/AKT/mTOR通路
聚ADP核糖聚合酶
生物技术
基因
聚合酶
生物化学
作者
Daniel J. Turnham,Michael P. Mullen,Nicholas Bullock,Kathryn Gilroy,Alison Richards,Radhika A. Patel,Marcos Quintela,Valérie S. Méniel,Gillian Seaton,Howard Kynaston,Richard W. E. Clarkson,Toby J. Phesse,Peter S. Nelson,Michael C. Haffner,John Staffurth,Helen Pearson
出处
期刊:Cells
[MDPI AG]
日期:2024-04-12
卷期号:13 (8): 673-673
标识
DOI:10.3390/cells13080673
摘要
As the treatment landscape for prostate cancer gradually evolves, the frequency of treatment-induced neuroendocrine prostate cancer (NEPC) and double-negative prostate cancer (DNPC) that is deficient for androgen receptor (AR) and neuroendocrine (NE) markers has increased. These prostate cancer subtypes are typically refractory to AR-directed therapies and exhibit poor clinical outcomes. Only a small range of NEPC/DNPC models exist, limiting our molecular understanding of this disease and hindering our ability to perform preclinical trials exploring novel therapies to treat NEPC/DNPC that are urgently needed in the clinic. Here, we report the development of the CU-PC01 PDX model that represents AR-negative mCRPC with PTEN/RB/PSMA loss and CTNN1B/TP53/BRCA2 genetic variants. The CU-PC01 model lacks classic NE markers, with only focal and/or weak expression of chromogranin A, INSM1 and CD56. Collectively, these findings are most consistent with a DNPC phenotype. Ex vivo and in vivo preclinical studies revealed that CU-PC01 PDX tumours are resistant to mCRPC standard-of-care treatments enzalutamide and docetaxel, mirroring the donor patient’s treatment response. Furthermore, short-term CU-PC01 tumour explant cultures indicate this model is initially sensitive to PARP inhibition with olaparib. Thus, the CU-PC01 PDX model provides a valuable opportunity to study AR-negative mCRPC biology and to discover new treatment avenues for this hard-to-treat disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI